Zai Lab Presents Updated Clinical Data for Zocilurtatug Pelitecan

The company reported clinically meaningful responses and a manageable safety profile in previously treated extrapulmonary neuroendocrine carcinomas. The Phase 1b/2 trial details are truncated in the supplied body.